Company news: Novartis and Boehringer Ingelheim

Novartis is setting itself up to dominate the generic dermatology market. The company said Thursday that generics subsidiary Sandoz is purchasing Fougera Pharmaceuticals for $1.5 billion in cash. The company estimated the merged businesses will have about $620 million in generic dermatology sales, the majority of which will be in the US.

Boehringer Ingelheim launched what it called the largest observational study of non-valvular atrial fibrillation (NVAF) patients. The goal is to enroll 56,000 patients from 50 countries and fill all 56,000 slots by the next decade. NVAF is a form of atrial fibrillation, which is known as an irregular heartbeat but which is also linked to stroke-causing blood clots. A registry, known as GLORIA-AF, will track the long-term impact of anti-clotting treatments, including warfarin, acetylsalicylic acid, BI's anticoagulant Pradaxa (dabigatran etexilate mesylate) and J&J/Bayer's blood thinner Xarelto (rivaroxaban).
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.